RxDoctor Payments Data

Ladan Hakimjavadi

Physician Assistant · Charlestown, MANPI 1144849415

Payments from drug & device makers

$3,151in general payments, 2019–2025

Across 124 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$546
  • AstraZeneca$454
  • E.r. Squibb & Sons, L.L.C.$393
  • Pfizer$356
  • Novartis$289
  • Johnson & Johnson$256
  • plus $857 from 13 others

What the payments were for

  • Food & beverage$3,137100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,151 in reported general payments places this provider in the 95th percentile of 3,507 physician assistant providers in Massachusetts.

See all physician assistant providers in Massachusetts

Medicare billing

Part B allowed, 2024
$25,829
Medicare patients
169
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$104,007
FarxigaDapagliflozin Propanediol27$31,121
EntrestoSacubitril/Valsartan20$24,119
JardianceEmpagliflozin18$13,267
Metoprolol Succinate127$1,317
Atorvastatin Calcium94$715
Losartan Potassium90$523
Hydralazine Hcl41$513
Furosemide62$348
Amlodipine Besylate88$328
Nitroglycerin15$320
Lisinopril36$281
Metoprolol Tartrate55$275
Digoxin19$237
Spironolactone48$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$356$104,007103 claims
AstraZenecaFarxiga$454$31,12127 claims
NovartisEntresto$289$24,11920 claims
Boehringer IngelheimJardiance$216$13,26718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,507 physician assistant providers in Massachusetts.

Other physician assistant in Charlestown

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →